ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

MBRX Moleculin Biotech Inc

3,98
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:00:24
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Moleculin Biotech Inc MBRX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 3,98 10:00:24
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,98
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
18.6.202423:00EDGAR2Form 8-K - Current report
14.6.202414:00EDGAR2Form 8-K - Current report
14.6.202414:00PRNUSMoleculin Announces Additional Positive Preliminary Interim..
12.6.202415:00PRNUSMoleculin to Present at the Virtual Investor Pitch..
07.6.202423:05EDGAR2Form S-3 - Registration statement under Securities Act of..
05.6.202414:55PRNUSMoleculin to Participate in the Virtual Investor Lunch Break..
16.5.202414:32EDGAR2Form 8-K - Current report
16.5.202414:32PRNUSMoleculin Abstract Accepted for Poster Presentation at the..
15.5.202414:38EDGAR2Form 8-K - Current report
15.5.202414:38PRNUSMoleculin Announces Commencement of NIH-Funded Phase 2..
14.5.202422:16EDGAR2Form 8-K - Current report
13.5.202416:53EDGAR2Form 8-K/A - Current report: [Amend]
13.5.202413:30EDGAR2Form 8-K - Current report
13.5.202413:30PRNUSMoleculin Reports First Quarter 2024 Financial Results and..
10.5.202422:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.5.202414:30EDGAR2Form 8-K - Current report
09.5.202414:30PRNUSMoleculin Announces U.S. Patent Issue Notification for..
08.5.202414:45PRNUSMoleculin to Report First Quarter 2024 Financial Results on..
08.5.202414:31EDGAR2Form 8-K - Current report
07.5.202422:13EDGAR2Form 8-K - Current report
07.5.202414:55EDGAR2Form 8-K - Current report
07.5.202414:55PRNUSMoleculin Reports Higher AML Complete Remission (CR) Rates..
02.5.202415:00PRNUSMoleculin to Host Virtual AML Clinical Day Featuring..
01.5.202414:50PRNUSMoleculin Announces Formation of Scientific Advisory Board..
18.4.202414:30PRNUSEuropean Medicines Agency (EMA) Grants Orphan Drug..
10.4.202414:30PRNUSMoleculin Announces Presentation of Positive Data..
28.3.202415:45PRNUSMoleculin to Present at the MedInvest Biotech & Pharma..
27.3.202414:25PRNUSMoleculin to Participate in the Virtual Investor Lunch..
27.3.202414:05PRNUSMoleculin Announces U.S. Patent Issue Notification for..
25.3.202412:30PRNUSMoleculin Announces Positive Interim Data in Annamycin..
22.3.202421:05PRNUSMoleculin Reports Full Year 2023 Financial Results
20.3.202412:30PRNUSMoleculin to Report Full Year 2023 Financial Results on..
20.3.202412:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
19.3.202421:30PRNUSMoleculin Announces Reverse Stock Split
12.3.202414:05PRNUSMoleculin to Present at the 36th Annual ROTH Conference
29.2.202414:30EDGAR2Form 8-K - Current report
22.2.202415:30EDGAR2Form 8-K - Current report
16.2.202423:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15.2.202415:15EDGAR2Form 8-K - Current report
14.2.202422:36EDGAR2Form 8-K - Current report
14.2.202422:33EDGAR2Form 8-K - Current report
13.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02.2.202423:05EDGAR2Form S-1 - General form for registration of securities under..
24.1.202414:50EDGAR2Form 8-K - Current report
24.1.202414:50PRNUSMoleculin Announces 2023 Year-End Annamycin Clinical Trials..
16.1.202423:00EDGAR2Form DEF 14A - Other definitive proxy statements
05.1.202423:15EDGAR2Form PRE 14A - Other preliminary proxy statements
05.1.202423:14EDGAR2Form 8-K - Current report
27.12.202313:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202323:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]

Kürzlich von Ihnen besucht

Delayed Upgrade Clock